Vimarsana
Biggest News Aggregation in the World

Greenfire Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Greenfire Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Greenfire Bio Today - Breaking & Trending Today

Slone Partners Places Gayarthri Swaminath as SVP of Discovery and Edward Moler as VP of Data Science at Juvena Therapeutics - Vimarsana News

Slone Partners Places Gayarthri Swaminath as SVP of Discovery and Edward Moler as VP of Data Science at Juvena Therapeutics

Published: February 9, 2023

South Riding, VA (PRWEB) February 08, 2023 -- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies,

Source: prweb.com
Related Topics:
Andhra PradeshUnited StatesGreenfire BioLinkedin JuvenaEdward MolerHanadie YousefGayathri SwaminathEddie MolerTara KochisTexasam UniversityCornell UniversityUniversity Of HyderabadUs Department Of EnergyQuest DiagnosticsStanford UniversityGe HealthcareSlone Partners President TaraVice PresidentData ScienceSenior Vice PresidentJuvena TherapeuticsTethys BiosciencePeople Are Our ScienceSlone PartnersSlone Partner
Slone Partners Places Gayathri Swaminath as SVP of Discovery and Edward Moler as VP of Data Science at Juvena Therapeutics - Vimarsana News

Slone Partners Places Gayathri Swaminath as SVP of Discovery and Edward Moler as VP of Data Science at Juvena Therapeutics

Published: February 9, 2023

South Riding, VA (PRWEB) February 08, 2023 -- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies,

Source: prweb.com
Related Topics:
Andhra PradeshUnited StatesGreenfire BioLinkedin JuvenaEdward MolerHanadie YousefGayathri SwaminathEddie MolerTara KochisTexasam UniversityCornell UniversityUniversity Of HyderabadUs Department Of EnergyQuest DiagnosticsStanford UniversityGe HealthcareSlone Partners President TaraVice PresidentData ScienceSenior Vice PresidentJuvena TherapeuticsTethys BiosciencePeople Are Our ScienceSlone PartnersSlone Partner
Green3Bio Announces Publication of Pre-Clinical Data Demonstrating SIK2 Inhibition (including GRN-300) Enhances PARP Inhibitor Activity Synergistically in Ovarian and Triple Negative Breast Cancers. - Vimarsana News

Green3Bio Announces Publication of Pre-Clinical Data Demonstrating SIK2 Inhibition (including GRN-300) Enhances PARP Inhibitor Activity Synergistically in Ovarian and Triple Negative Breast Cancers.

Published: June 24, 2022

/PRNewswire/ -- Green3Bio, a subsidiary of Greenfire Bio, today announced a publication in the Journal of Clinical Investigation1 led by researchers at The...

Source: prnewswire.com
Related Topics:
United StatesGreenfire BioZhen LuRobert BastSteve MorrisBajit GillWorld Cancer Research Fund InternationalUniversity Of Texas Md Anderson Cancer CenterAmerican Cancer SocietyCancer CenterScientific Advisory BoardClinical InvestigationAmerican CancerWorld Cancer Research FundClinical StudyRecurrent OvarianPrimary PeritonealFallopian Tube Cancers
Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022 - Vimarsana News

Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022

Published: May 31, 2022

/PRNewswire/ -- Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an update on...

Source: prnewswire.com
Related Topics:
United StatesGreenfire BioSiqing FuBajit GillUniversity Of Texas Md Anderson Cancer CenterPrnewswire Greenfire BioMd Anderson Cancer CenterWorld Cancer Research Fund InternationalMd Department Of Investigational Cancer TherapeuticsAmerican Cancer SocietyCancer CenterSalt Inducible KinasesPoster PresentationGynecologic CancerInvestigational Cancer TherapeuticsOvarian CancerHealth Care Amp Hospitals Medical Pharmaceuticals Biotechnology Pharmaceuticals Clinical Trials Amp Medical DiscoveriesTrade Show News
Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022 - Vimarsana News

Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022

Published: May 31, 2022

/PRNewswire/ -- Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an update on...

Source: prnewswire.com
Related Topics:
United StatesGreenfire BioSiqing FuBajit GillUniversity Of Texas Md Anderson Cancer CenterPrnewswire Greenfire BioMd Anderson Cancer CenterWorld Cancer Research Fund InternationalMd Department Of Investigational Cancer TherapeuticsAmerican Cancer SocietyCancer CenterSalt Inducible KinasesPoster PresentationGynecologic CancerInvestigational Cancer TherapeuticsOvarian Cancer